Intellectual Property Attorneys

Photo

The New Patent Law in New Zealand

The USPTO's January 7, 2019 Revised Patent Subject Matter Eligibility Guidance


Filing of U.S. Provisional Patent Applications in Languages Other Than English


Patent Opposition Procedure Returns to the Japanese Patent Office


Foreign Applicant Filing of Provisional Patent Applications - Post-AIA Considerations


Patent Claims Directed to Electromagnetic Radiation - Adaptive Approaches


Pharmaceutical Dose Forms – Design Patent and Trademark Intellectual Property


Hultquist IP Client ABL Enters Collaboration with Roche Diagnostics International


Avoiding Patent-Eligibility Issues Under 35 USC 101 in Chemical and Biotechnology Patent Applications Involving Patient Response and Genotype Assays


Strategic Focus in the New Patent World of First-to-File


The Prior User Defense to Patent Infringement Liability Under the AIA - Basic Considerations


FINAL ALERT – THE NEW PATENT ERA BEGINS MARCH 16, 2013


European Union Parliament Approves Unitary European Patent/Unified European Patent Court Package


Preemptive Drafting Approaches to Negative Claim Limitations That May Be Added in Post-Filing Prosecution


THE 2013 TAIWAN PATENT LAW REVISIONS


A Vote For Unity – The Emergence Of The Eurocentral Patent Court And Unitary European Patent


Korean Patent Act and Korean Pharmaceutical Affairs Act Revisions to Implement Korea-US Free Trade Agreement (KORUS FTA)


The Calculus of Patent Versus Trade Secret Protection Under the Newly Revised U.S. Patent Law


America Invents Act (“AIA”) – The Emergent Landscape of the Revised U.S. Patent Law


America Invents Act - PTO Fees Increase 15% on September 26, 2011


June 8, 2011 Amendment of the Japanese Patent Law


Branding And Minimizing The Risk Of Trademark Squatting In Foreign Markets


Ariad v. Lilly - Underscoring the Fundamentals


The U.S. Patent Law and US FDA Law - Pharmaceutical Patent Strategies


Streamlining Trademark Application Processing and Lowering Filing Costs


Korea Moves to Implement an “Orange Book”-Type Registration System for Patents Covering Approved Pharmaceuticals